Yatharth Hospital & Trauma Care Services Ltd

- There was a Qualified Institutional Placement (QIP) in December 2024, which added INR 6,145 million as security premium to reserves as a one-time event. - No explicit mention of a new equity fundraising planned immediately, but any new inorganic acquisitions or greenfield projects would require separate capex and potentially additional funding. - Promoters have pledged 8% of shares to raise INR 130 crores for personal investments, unrelated to the company’s funding needs. - The company plans capex of around INR 300 crores per year for the next 2-3 years for existing hospitals and expansions; inorganic acquisitions will require additional capital. - No direct statement on new debt fundraising; however, the company maintains a strong net cash position of INR 5,032 million bolstered by recent QIP. - The promoters aim to unpledge shares within a year as other properties get sold.

- Planned capex of around INR 300 crores for the current and next financial year, focused on existing 7 hospitals including New Delhi and Faridabad facilities. - Major investments include: - INR 100 crores for the 400-bedded Faridabad hospital for medical equipment and construction. - Around INR 55 crores for medical equipment at the New Delhi hospital. - Remaining capex allocated to Noida Extension, Greater Noida, Greater Faridabad, and brownfield expansions. - Capex per bed estimated at INR 7-8 million for existing hospitals. - Additional separate capex planned for inorganic acquisitions or new greenfield projects. - Intention to add at least one new hospital facility during the financial year. - Preference for owning 100% equity including land and buildings, avoiding asset-light or lease models. - Focus on expansions in NCR and nearby North Indian cities rather than new geographies.

- The company has maintained a strong growth trajectory, with a consistent ~30% year-on-year revenue growth over the past few years. - Confident about sustaining this growth momentum in revenue and profitability for FY '26 and beyond. - Expect continued volume growth: inpatient volume up 34%, outpatient volume up 16% YoY in FY '25. - New hospitals like Delhi and Faridabad are expected to perform similarly to Greater Faridabad hospital, contributing positively. - Specialty segments, especially super-specialties like oncology, neurosurgery, and cardiac surgery, are growing faster and expected to contribute 60-70% revenue per hospital. - ARPOB (average revenue per occupied bed) is increasing by more than 10% year-on-year. - Occupancy rates are steady around 80% for established hospitals, with potential for increases. - Working capital improvements and receivable days expected to reduce over 2-3 years, supporting better cash flows. Overall, a positive outlook with strong double-digit growth anticipated in sales, revenue, and volumes.

- The company has demonstrated a consistent 30% year-on-year growth in revenue over the past few years and expects to sustain this momentum going forward. - EBITDA margins are anticipated to stabilize around Q4 FY '25 levels, with only minor fluctuations of ±0.5%. - New hospitals (Delhi and Faridabad) are expected to become EBITDA breakeven within 12-15 months from operationalization, supporting future margin improvement. - Net profit grew 14% Y-o-Y in FY '25, with continued profitability growth expected. - Working capital improvement and receivable days reduction over 2-3 years should enhance cash flow and earnings quality. - The company remains optimistic about sustaining growth in earnings and operational profitability, driven by hospital ramp-ups, specialty segment expansion, and operational efficiency. - No explicit EPS guidance was provided, but sustained revenue and profit growth imply positive EPS trajectory.

The transcript does not explicitly mention the current or expected order book or pending orders for Yatharth Hospitals and Trauma Care Services Limited. However, relevant points related to expansions and acquisitions include: - The company plans to add at least 1 new facility in the current financial year, with more clarity expected in coming quarters. - Capex guidance includes around INR 300 crores over the next 2-3 years on existing hospitals, including new hospitals in New Delhi and Faridabad. - Additional inorganic acquisitions or greenfield projects will require separate capex, with acquisition costs estimated around INR 80 lakhs to INR 1 crore excluding land. - Growth and capacity additions suggest ongoing and future project pipeline but specific order book or pending orders details are not disclosed. If you need details on specific contracts or order inflow, the transcript does not provide this information.